Entries by admin

Neos Therapeutics Completes $20.6 Million Financing to Further Advance its Late-Stage ADHD Product Pipeline

Dallas/Fort Worth, TX (February 25, 2015) – Neos Therapeutics, Inc. (“Neos” or “the Company”), a specialty pharmaceutical company with a late-stage pipeline of innovative extended-release (“XR”) products for Attention-Deficit Hyperactivity Disorder (“ADHD”), today announced that it has completed an oversubscribed round of financing, raising a total of $20.6 million. The financing included investments by Presidio […]

ARCADIA BIOSCIENCES AND MAHYCO ACHIEVE PRODUCT DEVELOPMENT MILESTONE FOR WATER USE EFFICIENT RICE

– Technology Improves Yield Under Both Periodic and Severe Water Stress – DAVIS, Calif. and Jalna, INDIA (February 9, 2015) – CMEA Capital portfolio company Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, and Maharashtra Hybrid Seeds Co. Ltd. (Mahyco), a major seed […]

Wildcat Discovery Technologies DOE Vehicle Technologies Award Generates Promising Si Anode Electrolyte Leads

Wildcat identifies new non-carbonate electrolytes that outperform carbonate solutions. San Diego, CA – January 26, 2015 – CMEA Capital portfolio company Wildcat Discovery Technologies, a technology company using high throughput methods to develop improved battery materials, announced that it has achieved a significant milestone on its grant from the U.S. Department of Energy’s (DOE) Office […]

Neos Therapeutics Announces Submission of a New Drug Application for its Methylphenidate Extended Release Oral Disintegrating Tablet (XR-ODT) for the Treatment of ADHD

Dallas-Fort Worth, TX (January 12, 2015) – Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a late-stage pipeline of innovative extended release (“XR”) products for Attention-Deficit Hyperactivity Disorder (“ADHD”), announced today that it has submitted a New Drug Application (NDA) for its methylphenidate XR-ODT drug candidate, NT-0102, an ADHD medication based on its patented XR-ODT technology. Orally […]

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

– Statistically Significant Data from Phase 2 Study Support Safety and Efficacy of Once Daily Dosing of NK-1 Antagonist, VPD-737 (serlopitant) — SOUTH SAN FRANCISCO, Calif., Dec. 17, 2014 /PRNewswire/ — Tigercat Pharma, Inc. today announced positive results of a Phase 2 study evaluating the investigational oral NK-1 receptor antagonist VPD-737 (serlopitant), for the treatment of patients […]

Neos Therapeutics Announces Issuance of Key Patent Covering its Extended Release Oral Disintegrating Tablet (XR-ODT) Platform Technology

Dallas-Fort Worth, TX (October 8, 2014) – Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release (“XR”) products for Attention Deficit Hyperactivity Disorder (“ADHD”), announced today that is has been granted a key patent (US […]

Jobvite Secures $25 Million Of Expansion Capital Led By Catalyst Investors

San Mateo, Calif. — (October 7, 2014) — CMEA Capital portfolio company Jobvite, the comprehensive recruiting solution for the world’s fastest growing companies, today announced that it closed $25 million in Series D funding led by growth equity firm Catalyst Investors. Catalyst joins existing investors CMEA, ATA Ventures and Trident Capital. The investment serves as a […]

ARCADIA BIOSCIENCES AND ARBORGEN TO DEVELOP DROUGHT-TOLERANT AND NITROGEN-EFFICIENT EUCALYPTUS TREES

– Improved Varieties Will Enhance Productivity and Sustainability of Purpose-grown Forests – DAVIS, Calif. (October 7, 2014) –  CMEA Capital portfolio company Arcadia Biosciences, Inc., an agricultural biotechnology company, and ArborGen announced an agreement to incorporate Arcadia’s water use efficiency (WUE) and nitrogen use efficiency (NUE) technologies in eucalyptus trees. The license agreement will allow ArborGen, […]

Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic Tussionex® (Extended Release Hydrocodone Polistirex/Chlorpheniramine Polistirex) from Chiesi USA and Coating Place, Inc.

Dallas-Fort Worth, TX, Cary, NC and Verona, WI (September 8, 2014) – CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release (“XR”) products for Attention Deficit Hyperactivity Disorder (“ADHD”), announced today the completion of the acquisition […]

Petrobras and Foro Energy Announce Signing of Technology Cooperation Agreement

HOUSTON–(BUSINESS WIRE) – August 26th, 2014 Petrobras and Foro Energy today announced the signing of a Technology Cooperation Agreement (TCA) for high power laser drilling research and development. The program with the Leopoldo Americo Miguez de Mello Research & Development Center (CENPES) will focus on developing a next generation high power laser drilling system. The TCA […]